India Activists Claim U.S. Steps Up Lobbying Against Compulsory License
This article was originally published in PharmAsia News
Foreign drug makers complaining about India's use of its compulsory licensing law to allow a generic of a Bayer patent-protected cancer drug appear to have the active backing of the U.S. government.
You may also be interested in...
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.